Historical analysis of PAI-I from its discovery to its potential role in cell motility and disease

被引:230
作者
Dellas, C [1 ]
Loskutoff, DJ [1 ]
机构
[1] Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA
关键词
PAI-I; vascular disease; fibrosis; obesity; cancer;
D O I
10.1160/TH05-01-0033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although plasminogen activator inhibitor I (PAI-I) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration. PAI-I also differs from other serine protease inhibitors (serpins) in that it is a trace protein in plasma, it has a short half-life in vivo, its synthesis is highly regulated, and it binds to the adhesive glycoprotein vitronectin (VN) with high affinity and specificity. These unique and diverse properties of PAI-I probably account for the many observations in the literature that correlate abnormalities in PAI-I gene expression with a variety of pathological conditions. In this review, we discuss the discovery, origin, properties and regulation of PAI-I, and then speculate about its potential role in vascular disease, fibrosis, obesity and the metabolic syndrome, and cancer.
引用
收藏
页码:631 / 640
页数:10
相关论文
共 150 条
[1]   AN ASSAY FOR TRANSFORMING GROWTH-FACTOR-BETA USING CELLS TRANSFECTED WITH A PLASMINOGEN-ACTIVATOR INHIBITOR-1 PROMOTER LUCIFERASE CONSTRUCT [J].
ABE, M ;
HARPEL, JG ;
METZ, CN ;
NUNES, I ;
LOSKUTOFF, DJ ;
RIFKIN, DB .
ANALYTICAL BIOCHEMISTRY, 1994, 216 (02) :276-284
[2]   Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].
Alessi, MC ;
Peiretti, F ;
Morange, P ;
Henry, M ;
Nalbone, G ;
JuhanVague, I .
DIABETES, 1997, 46 (05) :860-867
[3]   PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING [J].
ANDREASEN, PA ;
RICCIO, A ;
WELINDER, KG ;
DOUGLAS, R ;
SARTORIO, R ;
NIELSEN, LS ;
OPPENHEIMER, C ;
BLASI, F ;
DANO, K .
FEBS LETTERS, 1986, 209 (02) :213-218
[4]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[5]   MAJOR CIRCADIAN FLUCTUATIONS IN FIBRINOLYTIC FACTORS AND POSSIBLE RELEVANCE TO TIME OF ONSET OF MYOCARDIAL-INFARCTION, SUDDEN CARDIAC DEATH AND STROKE [J].
ANDREOTTI, F ;
DAVIES, GJ ;
HACKETT, DR ;
KHAN, MI ;
DEBART, ACW ;
ABER, VR ;
MASERI, A ;
KLUFT, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (09) :635-637
[6]   DIURNAL-VARIATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RAPID INHIBITOR (PAI-1) [J].
ANGLETON, P ;
CHANDLER, WL ;
SCHMER, G .
CIRCULATION, 1989, 79 (01) :101-106
[7]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[8]   CONFOCAL FLUORESCENCE MICROSCOPY OF UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR AND CATHEPSIN-D IN HUMAN MDA-MB-231 BREAST-CANCER CELLS MIGRATING IN RECONSTITUTED BASEMENT-MEMBRANE [J].
BASTHOLM, L ;
NIELSEN, MH ;
DEMEY, T ;
DANO, K ;
BRUNNER, N ;
HOYERHANSEN, C ;
RONNE, E ;
ELLING, F .
BIOTECHNIC & HISTOCHEMISTRY, 1994, 69 (02) :61-67
[9]  
BAVENHOLM P, 1995, THROMB HAEMOSTASIS, V73, P568
[10]   DEPRESSED BRONCHOALVEOLAR UROKINASE ACTIVITY IN PATIENTS WITH ADULT RESPIRATORY-DISTRESS SYNDROME [J].
BERTOZZI, P ;
ASTEDT, B ;
ZENZIUS, L ;
LYNCH, K ;
LEMAIRE, F ;
ZAPOL, W ;
CHAPMAN, HA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (13) :890-897